Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 692 versus Ocrevus in relapsing-remitting multiple sclerosis
2024-512914-16-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing ABP 692 with Ocrevus (2 arms). Primary endpoints: AUC0-d15 following infusion 1 of the initial dose and AUC0-inf of the entire initial dose. Planned start Sep 2025; status: authorised.
02
Drugs
ABP 692ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-512914-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512914-16-00.